Skip to main content

Therapeutische Konzepte bei verschiedenen Demenzformen

  • Chapter
Parkinson plus

Zusammenfassung

Wenn man sich mit der Behandlung der Demenz befaßt, muß man zunächst klären, wie man diese Funktionsstörung definieren will. Früher wurde die Demenz als eine dauernde, irreversible und progrediente Störung intellektueller Funktionen und der Persönlichkeit angesehen. Diese Betrachtungsweise ist zumindest im angloamerikanischen Sprachraum aufgegeben worden, nachdem gezeigt werden konnte, daß es eine nicht unbeträchtliche, auf 10–30% geschätzte Zahl von potentiell reversiblen Demenzformen gibt (Marsden u. Harrison 1972; Freemon 1976; Cummings et al. 1980). Für diese Demenzformen kommen eine ganze Reihe von Ursachen in Betracht, die einmal im Gehirn selbst liegen können, zum anderen auf metabolischen, toxischen, entzündlichen und kreislaufabhängigen Einwirkungen beruhen können (Tabelle 1). Zweifellos läßt sich darüber diskutieren, ob es zweckmäßig ist, diese symptomatischen, psychoorganischen Funktionsstörungen als reversible Demenz zu klassifizieren. Es ist jedoch nicht zu verkennen, daß eine solche Differenzierung dazu beitragen kann, große diagnostische Sorgfalt walten zu lassen und einem therapeutischen Nihilismus entgegenzuwirken. Das erscheint in der überwiegend betroffenen höheren Altersgruppe von erheblicher Bedeutung. Das therapeutische Vorgehen wird sich in diesen Fällen soweit wie möglich auf die Ausschaltung der Demenzursache richten. Auf die im einzelnen zu ergreifenden Maßnahmen und die jeweiligen Erfolgsaussichten soll hier nicht näher eingegangen werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adolfson R, Gottfries CG, Oreland L, Roos BE, Winblad B (1978) Reduced levels of catecholamines in the brain and increased activity of monoamine oxidase in platelats in Alzheimer’s disease: therapeutic implications. In: Katzman R, Terry RD, Bick KL (eds) Senile Dementia and Related Disorders. Raven Press, New York, pp 441–451

    Google Scholar 

  • Adolfson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135:216–223

    Article  Google Scholar 

  • Adolfson R, BrÅne G, Bucht G, Karlsson I, Gottfries CG, Person S, Winblad B (1982) A double-blind study with levodopa in dementia of Alzheimer type. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 469–473

    Google Scholar 

  • Bajada S (1982) A trial of choline chloride and physostigmine in Alzheimer’s dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 427–432

    Google Scholar 

  • Barbeau A (1978) Emerging treatments: replacement therapy with choline or lecithin in neurological diseases. Can J Neurol Sci 5:157–160

    PubMed  CAS  Google Scholar 

  • Barbeau A (1980) Lecithin in Parkinson’s disease. J Neurol Trans [Suppl]16:187–193

    Google Scholar 

  • Bartus RT, Dean RL, Sherman K, Friedman E, Beer B (1981) Profound effects of combining choline and Piracetam on memory enhancement and cholinergic funetion in aged rats. Neurobiol Aging 2:105–111

    Article  PubMed  CAS  Google Scholar 

  • Becker H, Schneider E, Hacker H, Fischer PA (1979) Cerebral atrophy in Parkinson’s disease - represented in CT. Arch Psychiatr Nervenkr 227:81–88

    Article  PubMed  CAS  Google Scholar 

  • Bohus B (1979) Effects of ACTH-like neuropeptides on animal behaviour and man. Pharmacology 18:113–122

    Article  PubMed  CAS  Google Scholar 

  • Bowen DM, Smith DB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459–495

    Article  PubMed  CAS  Google Scholar 

  • Boyd WD, Graham-White J, Blackwood G, Glen I, McQueen J (1977) Clinical effects of choline in Alzheimer senile dementia. Lancet II:711

    Article  Google Scholar 

  • Chase TN, Durso R, Fedio P, Tamminga CA (1982) Vasopressin treatment of cognitive deficits in Alzheimer’s disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19, Raven Press, New York, pp 457–461

    Google Scholar 

  • Christee JE, Blackburn IM, Glen A, Ziesel S, Shering A, Yates CM (1979) Effects of choline and lecithin on CSF choline levels and on cognitive function in patients with presenile dementia of the Alzheimer type. In: Barbeau A, Growdon JH, Wurtman RJ (eds) Nutrition and Brain. Vol 5: Choline and Lecithin in Brain Disorders. Raven Press, New York, pp 377–387

    Google Scholar 

  • Christie JE (1982) Physostigmine and arecoline infusions in Alzheimer’s disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 413–419

    Google Scholar 

  • Cook P, James I (1981) Cerebral vasodilators. N Engl J Med 305:1508–1564

    Article  PubMed  CAS  Google Scholar 

  • Cummings J, Benson DF,Lo Verme ST (1980) Reversible dementia. JAMA 243:2434–2439

    Article  PubMed  CAS  Google Scholar 

  • Cummings J (1983) Treatable dementias. In: Mayeux R, Rosen WG (eds) The dementias. Raven Press, New York, pp 165–183

    Google Scholar 

  • Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer disease. Lancet II:1403

    Article  Google Scholar 

  • Davis KL, Mohs RC, Tinklenberg JR (1979) Enhancement of memory by physostigmine. N Engl J Med 301:946

    PubMed  CAS  Google Scholar 

  • Davis KL, Mohs RC (1982) Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139:1421–1424

    PubMed  CAS  Google Scholar 

  • de Wied D (1964) Influence of anterior pituitary on avoidance learning and escape behaviour. Am J Physiol 207:255–259

    Google Scholar 

  • de Wied D (1965) The influence of the posterior and intermediate lobe of the pituitary and pituitary Peptides on the maintenance of a conditioned avoidance response in rats. Int J Neuropharmacol 4:157–167

    Article  Google Scholar 

  • de Wied D (1969) Effects of peptide hormones on behaviour. In: Ganong WF, Martini L (eds) Frontiers in Neuroendocrinology. University Press, London New York, pp 1484–1486

    Google Scholar 

  • de Wied D, van Wimersma Greidanus TB, Bohus B, Urban I, Gispen WH (1976) Vasopressin and memory consolidation. In: Corner M, Swaab DF (eds) Perspectives in Brain Research. Progress in Brain Research Vol 45. Elsevier, New York, pp 181–191

    Google Scholar 

  • Dimond SJ (1975) Use of a nootropic substance to increase the capacity for verbal learning and memory in normal man. In: Agnoli A (ed) Proceedings of the Symposium ,Nooanaleptic and nootropic drugs’. Rome, pp 107–110

    Google Scholar 

  • Dimond SJ, Brouwers EYM (1976) Increase in the power of human memory in normal man through the use of drugs. Psychopharmacol 49:307

    Article  CAS  Google Scholar 

  • Drachman DA (1977) Memory and cognitive function in man: Does the cholinergic System have a specific role? Neurology 27:783–790

    PubMed  CAS  Google Scholar 

  • Drachman DA, Stahl S (1975) Extrapyramidal dementia and levodopa. Lancet I:809

    Article  Google Scholar 

  • Dysken MW, Foval P, Harris CM, Noronha A, Bergen D, Hoeppner T, Davis JM (1982) Lecithin administration in patients with primary degenerative dementia and in normal volunteers. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 385–392

    Google Scholar 

  • Etienne P, Gauthier S, Dastoor D, Collier B, Ratner J (1978 a) Lecithin in Alzheimer disease. Lancet II:1206

    Article  Google Scholar 

  • Etienne P, Gauthier S, Johnson G, Collier B, Mendis T, Dastoor D, Cole M (1978 b) Clinical effects of choline in Alzheimer’s disease. Lancet I:508–509

    Article  Google Scholar 

  • Etienne P, Dastoor D, Gauthier S, Ludwick R, Collier B (1982) Lecithin in the treatment of Alzheimer’s Disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 369–372

    Google Scholar 

  • Ferris SH, Sathanathan G, Reisberg B, Gershon S (1979) Long-term choline treatment of me-mory-impaired elderly patients. Science 250:1039–1040

    Article  Google Scholar 

  • Ferris SH, Reisberg B, Crook T, Friedman E, Schneck MK, Mir P, Sherman KA, Corwin J, Gershon S, Bartus RT (1982) Pharmacologic treatment of senile dementia: Choline, L-Dopa, Piracetam and Choline plus Piracetam. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman

    Google Scholar 

  • RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 475–481

    Google Scholar 

  • Fogelholm R, Waltimo O, Putkonen AR, Laaksonen R (1974) Bencyclan - a new vasodilator drug - in the treatment of patients with ischemic cerebral infarction. Ann Clin Res 6:93–98

    PubMed  CAS  Google Scholar 

  • Freemon FR (1976) Evaluation of patients with progressive intellectual deterioration. Arch Neurol 33:658–659

    PubMed  CAS  Google Scholar 

  • Garcia CA, Tweedy JR, Blass JP, McDowell FH (1982) Lecithin and Parkinson Dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 443–449

    Google Scholar 

  • Gobert J (1972) Genese d’un medicament, le Piracetam, metabolisation et recherche biochimique. J Pharm Belg 27:281–304

    CAS  Google Scholar 

  • Gold PE, Rose RP, Spanis CW, Hankins LL (1977) Retention deficit for avoidance training in hypophysectomized rats: time-dependent enhancement of retention Performance with ACTH injections. Horm Behav 8:363–371

    Article  PubMed  CAS  Google Scholar 

  • Goldfarb AL, Hochstadt NJ, Jacobson JH (1972) Hyperbaric oxygen treatment of organic mental Syndrom in aged persons. J Gerontol 27:212–217

    PubMed  CAS  Google Scholar 

  • Gottfries CG, Gottfries I, Roos BE (1969) The investigation of homovanillic acid in the human brain and its correlation to senile dementia. Br J Psychiatry 115:563–574

    Article  PubMed  CAS  Google Scholar 

  • Gottfries CG, Gottfries I, Roos BE (1970) Homovanillic acid and 5-hydroxyindole-acetic acid in cerebrospinal fluid related to rated mental and motor impairment in senile dementia and presenile dementia. Acta Psychiatr Scand 46:99–105

    PubMed  CAS  Google Scholar 

  • Greenwald BS, Davis KL (1983) Experimental Pharmacology of Alzheimer Disease. In: Mayeux R, Rosen WG (eds) The Dementias. Adv Neurol 38:87–102

    Google Scholar 

  • Hachinski VC, Iliff LD, Zilhka E, du Boulay GHD, McAllister VL, Marshall J, Russel RWR, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637

    PubMed  CAS  Google Scholar 

  • Herrschaft H (1976) Die Therapie der cerebralen Mangeldurchblutung. Nervenarzt 47:639–650

    PubMed  CAS  Google Scholar 

  • Heyman A, Logue P, Wilkinson W, Holloway D, Harwitz B (1982) Lecithin therapy of Alzheimer’s Disease: a preliminary report. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 373–378

    Google Scholar 

  • Horowski R, McDonald RJ (1983) Experimental and clinical aspects of ergot derivates used in the treatment of age-related disorders. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging Brain and Ergot Alkaloids. Aging, Vol 23. Raven Press, New York, pp 283–303

    Google Scholar 

  • Hoyer S, Oesterreich K, Stoll KD (1977 a) Effects of pyritinol-HCl on blood flow and oxidative metabolism of the brain in patients with dementia. Arzneimittelforsch 27:671–674

    PubMed  CAS  Google Scholar 

  • Hoyer S, Krüger G, Oesterreich K, Weinhardt F (1977 b) Effects of drugs on cerebral blood flow and oxidative metabolism in patients with dementia. In: Meyer JS, Lechner H, Reivich M (eds) Cerebral vascular disease. Excerpta Medica, Amsterdam Oxford, pp 25–28

    Google Scholar 

  • Hoyer S (1978) Das organische Psychosyndrom. Überlegungen zur Hirndurchblutung, zum Hirnstoffwechsel und zur Therapie. Nervenarzt 49:201–207

    CAS  Google Scholar 

  • Hoyer S (1982) Einfluß von Piracetam auf Durchblutung und Stoffwechsel. In: Platt D (Hrsg) Piracetam in der Geriatrie. Schattauer, Stuttgart New York, S 77–85

    Google Scholar 

  • Hughes CP, Siegel BA, Coxe WS, Gado MH, Grubb RL, Coleman RE, Berg L (1978) Adult idiopathic communicating hydrocephalus with and without shunting. J Neurol Neurosurg Psychiatry 41:961–971

    Article  PubMed  CAS  Google Scholar 

  • Jacobs EA, Winter PM, Alvis HJ (1969) Hyperoxygenation effect on cognitive function in the aged. N Engl J Med 281:753–757

    Article  PubMed  CAS  Google Scholar 

  • Kaye WH, Weingartner H, Gold Ph, Ebert MH, Gillin JC, Sitaram N, Smallberg S (1982) Cognitive effects of cholinergic and vasopressinlike agents in patients with primary degenerative dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York pp 433–442

    Google Scholar 

  • Kristensen V, Olsen M, Thilgaard A (1977) Levodopa treatment of presenile dementia. Acta Psychiatr Scand 55:41–51

    Article  PubMed  CAS  Google Scholar 

  • Kugler J, Oswald WD, Herzfeld U, Sens R, Pingel J, Wenzel D (1978) Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103:456–462

    Article  PubMed  CAS  Google Scholar 

  • Lewis C, Ballinger BR, Presley AS (1978) Trial of levodopa in senile dementia. Br Med J I:550

    Article  Google Scholar 

  • Marsden CD, Harrison MFG (1972) Outcome of investigation with presenile dementia. Br Med J II:249–252

    Article  Google Scholar 

  • Mayeux R, Stern Y (1983) Intellectual dysfunction and dementia in Parkinson disease. In: Mayeux R, Rosen WG (eds) The dementias. Adv Neurol 38:211–227

    Google Scholar 

  • Meynaud A, Grand M, Fontaine L (1973) Effect of naftidrofuryl upon energy metabolism of the brain. Arzneimittelforsch 23:1431–1436

    PubMed  CAS  Google Scholar 

  • Mohs RC, Davis KL, Tinklenberg JR, Hollister LE, Yesavage JA, Kopell BS (1979) Choline Chloride treatment of memory deficits in one elderly. Am J Psychiatry 136:126–1277

    Google Scholar 

  • Pede JP, Schtmpfessel L, Crokaert R (1971) The action of piracetam on oxydative phosphorylation. Arch Int Physiol Biochem 79:1036

    Google Scholar 

  • Perry EK, Perry RH, Blessed G, Tomlison BE (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet I:189

    Article  Google Scholar 

  • Peters BM, Levin HS (1979) Effects of physostigmin and lecithin on memory in Alzheimer’s disease. Ann Neurol 6:219–221

    Article  PubMed  CAS  Google Scholar 

  • Peters BM, Levin HS (1982) Chronic oral physostigmine and lecithin administration in memory disorders of aging. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 421–426

    Google Scholar 

  • Platt D (1973) Age dependent determinations of lysosomal enzyme activities in the liver and brain as well as the measurement of cytoplasmic enzyme activities in the blood or Piracetam pretreated rats. Exp Gerontol 8:315–324

    Article  PubMed  CAS  Google Scholar 

  • Platt D, Hering H, Hering FJ (1974) Messungen lysosomaler Enzym-Aktivitäten sowie von Leuzin-Inkorporationsraten im Gehirn junger und alter Ratten nach Gabe von Piracetam. Arzneimittelforsch 24:1588–1590

    PubMed  CAS  Google Scholar 

  • Pomara N, Goodnick PJ, Brinkman SD, Domino E, Gershon S (1982) A dose-response study of lecithin in the treatment of Alzheimer’s disease. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New York, pp 379–383

    Google Scholar 

  • Pope A, Hess HH, Lewin E (1965) Microchemical pathology of the cerebral cortex in pre-senile dementias. Trans Am Neurol Assoc 89:15–16

    Google Scholar 

  • Renvoize EB, Jerram T (1979) Choline in Alzheimer’s disease. N Engl J Med 301:330

    PubMed  CAS  Google Scholar 

  • Rigter H, van Riezen H, de Wied D (1974) The effects of ACTH and Vasopressin analogues in CO2-induced retrograde amnesia in rats. Physiol Behav 13:381–388

    Article  PubMed  CAS  Google Scholar 

  • Rochus L, Reuse JJ (1972) Chlorpromazine, piracetam et metabolisme des phospholipides du cerveau chez le rat. CR Soc Biol (Paris) 166:975–978

    CAS  Google Scholar 

  • Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1979) Pathologic verification of ischemic score in differentiation of dementias. Ann Neurol 7:486–488

    Article  Google Scholar 

  • Schneider E, Fischer PA, Jacobi P (1976) Bencyclan (Fludilat) in der Behandlung lokaler Hirndurchblutungsstörungen. Med Klin 71:1611–1616

    PubMed  CAS  Google Scholar 

  • Schneider E, Becker H, Fischer PA, Grau H, Jacobi P, Brinkmann R (1979 a) The course of brain atrophy in Parkinson’s disease. Arch Psychiatr Nervenkr 227:89–95

    Article  PubMed  CAS  Google Scholar 

  • Schneider E, Fischer PA, Jacobi P, Becker H, Hacker H (1979 b) The significance of cerebral atrophy for the symptomatology of Parkinson’s disease. J Neurol Sci 42:187–197

    Article  PubMed  CAS  Google Scholar 

  • Schneider E, Jacobi P, van Riezen H, Voerman JWA, Fischer PA (1981) Wirkungen synthetischer Neuropeptide auf die hirnorganische Leistungsinsuffizienz. Ergebnisse der Anwendung von ACTH4_10 und des ACTH4_9-Analogon. Pharmacopsychiatria 14:155–159

    CAS  Google Scholar 

  • Schneider E, Fischer PA, Jacobi P, Becker H (1982) Demenz beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Roches Basel S 93–114

    Google Scholar 

  • Scholing WE, Clausen HD (1974) Psychotrope Leistungssteigerung durch ein stoffwechselaktives Hämoderivat bei Alterspatienten. Aktuel Gerontol 4:521–530

    Google Scholar 

  • Signoret JL, Whileley AL, L’hermitte F (1978) Influence of choline on amnesia in early Alzheimer’s disease. Lancet I:333–335

    Google Scholar 

  • Sitaram N, Weingartner H, Caine ED, Gillin JC (1978a) Choline: Selective enhancement of serial learning and encoding of low imagery words in man. Life Sci 22:1555–1560

    Article  PubMed  CAS  Google Scholar 

  • Sitaram N, Weingartner H, Gillin JC (1978b) Human serial learning: Enhancement with arecoline and impairment with scopolamine correlated with Performance on placebo. Science 201:274–276

    Article  PubMed  CAS  Google Scholar 

  • Smith CM, Swash LM, Exton-Smith A, Phillips MA, Overstall PW, Piper ME, Baily MR (1978) Choline therapy in Alzheimer’s disease. Lancet II:318

    Article  Google Scholar 

  • Squitieri G, Cervone A, Agnoli A (1975) A study on shorterm memory in man. Interactions with nooanaleptic and nootropic drugs. In: Agnoli A (ed) Proceedings of the Symposium ,Noo-analeptic and Nootropic Drugs’. Rome, pp 111–121

    Google Scholar 

  • Sternlieb I, Scheinberg IH (1964) Penicillamine therapy for hepatolenticular degneration. JAMA 189:748–754

    PubMed  CAS  Google Scholar 

  • Suchenwirth RMA (1982) Die Behandlung hirnorganisch bedingter psychischer Störungen mit Piracetam. In: Platt D (Hrsg) Piracetam in der Geriatrie. Schattauer, Stuttgart New York, S 61–68

    Google Scholar 

  • Thompson LW, Davis GC, Obrist WD, Heyman A (1976) Effects of hyperbaric oxygen on behavioural and physiological measures in elderly demented patients. J Gerontol 31:23–28

    PubMed  CAS  Google Scholar 

  • Tinklenberg JR, Pigache R, Pfefferbaum A, Berger PA (1982) Vasopressin peptides and dementia. In: Corkin S, Davis KL, Growdon JH, Usdin E, Wurtman RJ (eds) Alzheimer’s Disease: A Report of Progress in Research. Aging, Vol 19. Raven Press, New Yrok, pp 463–468

    Google Scholar 

  • Tomlinson BE, Blessed G, Roth M (1968) Observations on the brains of non-demented old people. J Neurol Sci 7:331–356

    Article  PubMed  CAS  Google Scholar 

  • Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11:205–242

    Article  PubMed  CAS  Google Scholar 

  • Tweedy JR, Garcia CA (1982) Lecithin treatment of cognitively impaired Parkinson’s patients. Eur J Clin Invest 12:87–90

    Article  PubMed  CAS  Google Scholar 

  • Udvarhelyi GB, Wood JH, James AE jr, Bartlet D (1975) Results and complications in 55 shunted patients with normal pressure hydrocephalus. Surg Neurol 3:271–275

    PubMed  CAS  Google Scholar 

  • van Riezen H, Rigter H (1978) Mögliche Bedeutung ACTH-ähnlicher Peptide für das geistige Leistungsvermögen des Menschen. Arzneimittelforsch 28(II): 1294–1296

    PubMed  Google Scholar 

  • van Woert MH, Yahr M, Heninger G, Ratney V, Bowers MH (1970) L-Dopa in senile dementia. Lancet I:573–574

    Article  Google Scholar 

  • Wedl W, Suchenwirth RMA (1977) Eigenwirkungen des GABA-Abkömmlings Piracetam im doppelten Blindversuch bei Gesunden. Nervenarzt 48:58–60

    PubMed  CAS  Google Scholar 

  • Woelk H (1979) Effects of piracetam on the incorporation of 32P into phospholipids of neurons and glial cells isolated from rabbit cerebral cortex. Pharmacopsychiatrica 12:251–256

    Article  CAS  Google Scholar 

  • Wurtman RJ, Magil SG, Reinstein DK (1981) Piracetam diminishes hippocampal acetylcholine levels in rats. Life Sci 28:1091–1093

    Article  PubMed  CAS  Google Scholar 

  • Yesavage J, Tinklenberg JR, Hollister LE, Berger PA (1979) Vasodilators in senile dementias: A review of the literature. Arch Gen Psychiatry 36:220–223

    PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin-Heidelberg

About this chapter

Cite this chapter

Schneider, E., Fischer, PA., Jacobi, P. (1984). Therapeutische Konzepte bei verschiedenen Demenzformen. In: Fischer, PA. (eds) Parkinson plus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69839-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-69839-2_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-13566-1

  • Online ISBN: 978-3-642-69839-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics